ClinicalTrials.gg
Not yet recruitingNCT06384599Updated Oct 13, 2026

VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study

An interventional study of VT Cryoablation System in Ventricular Tachycardia, sponsored by Adagio Medical. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Tachycardia, Ventricular with a site in United Kingdom — 12 open to participants now, 14 under way, none of them phase 3. Tachycardia, Ventricular · United Kingdom.

Planned enrollment
11th of 24
130 · median 94
Started
2027
the only one that year
No phase
23 of 38
6 open now
Primary completion
2027-05
later than 8 of 13 live
Registered
33rd of 38
by date
Lead sponsor
1 of 38
Adagio Medical

Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, this one is the 11th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 23 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 33rd registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

12 of the 38 studies in Tachycardia, Ventricular with a site in United Kingdom are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Tachycardia, Ventricular with a site in United Kingdom, or all of them as a file.
02

Study summary

The PMCF is a prospective, single-arm, multi-center, controlled study of up to 130 patients designed to collect safety and performance data regarding the use of the Adagio VT Cryoablation System in the treatment of recurrent ventricular tachycardia.

Read the detailed description

This VT Post-Market Clinical Follow-up (PMCF) study continues collecting additional information about the Adagio Medical VT Cryoablation System in real world clinical settings.

03

Conditions studied

  • Ventricular Tachycardia

Keywords

  • Monomorphic Ventricular Tachycardia
  • VT
  • Cryoablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IC 1 Male or female the ages of ≥ 18 years
  • IC 2 Planned ablation procedure according to the indication for use of the Adagio VT Cryoablation System
  • IC 3 Subject willing to comply with study requirements and give
  • IC4 Subject has or will be receiving an ICD prior to hospital discharge

Exclusion criteria

Exclusion Criteria:

  • EC 1 In the opinion of the investigator, any known to a ventricular tachycardia procedure with the Adagio VT Cyroablation System as indicated in the device Instructions For Use (IFU)
  • EC 2 Subject is enrolled in a study that has not been approved for concurrent enrollment by the sponsor
  • EC 3 Any other condition that, in the judgement of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a of less than six months, extensive travel away from the research center)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    VT Cryoablation Arm

    all subjects will receive a cryoablation procedure with the VT System and be followed up for 6-month

    Device: VT Cryoablation System

Interventions

  • DeviceVT Cryoablation System

    All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)

06

What researchers measure

Primary outcomes

  1. Primary Performance Endpoint

    Freedom from ventricular tachycardia or appropriate ICD intervention until the end of the 6 month follow up period

    Time frame: 6 months

  2. Primary Safety Endpoint

    Freedom from device / procedure related major adverse events (MAE) during and after the ablation procedure through 30 days follow up. MAEs include: * Death * MI * Cardiac perforation / pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion * Heart valve damage resulting in moderate to severe regurgitation * Access site complications requiring surgical intervention * Pericarditis * Heart block requiring a pacemaker implant * Other serious adverse device effects (SADEs).

    Time frame: 30 Days

Secondary outcomes

  1. Secondary Performance Endpoint

    Analysis of the proportion of subjects with non-inducible clinical monomorphic VT at the conclusion of the initial cryotherapy ablation procedure.

    Time frame: During the procedure

  2. Secondary Safety Endpoint

    Freedom from serious adverse events at 6M following discharge.

    Time frame: 6 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for May 2027, 4 months later.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's planned 4 months is below that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 25, 2024
StartEst.
Jan 1, 2027was Sep 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Jan 1, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Start date Sep 1, 2026→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06384599
Lead sponsor
Adagio Medical
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Jan 1, 2027 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Nabil Jubran
Contact
njubran@adagiomedical.com
(949) 348-1188
Doug Kurschinski
Contact
dkurschinski@adagiomedical.com
(949) 348-1188

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion